- Home
- CYRX vs PGEN Comparison
CYRX vs PGEN Comparison
Compare CYRX & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CYRX | PGEN |
|---|---|---|
| Founded | 1999 | 1998 |
| Country | United States | United States |
| Employees | 1100 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 814.9M | 2.8B |
| IPO Year | 2008 | 2013 |
Fundamental Metrics
Financial Performance| Metric | CYRX | PGEN |
|---|---|---|
| Price | $17.31 | $8.06 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 4 |
| Target Price | ★ $19.33 | $13.65 |
| AVG Volume (30 Days) | 452.6K | ★ 3.6M |
| Earning Date | 11-03-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 156.22 | N/A |
| EPS | N/A | ★ 0.03 |
| Revenue | $176,177,000.00 | ★ $230,981,000.00 |
| Revenue This Year | $10.96 | $2,365.68 |
| Revenue Next Year | $9.97 | $85.75 |
| P/E Ratio | ★ N/A | $271.00 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.61 | $2.99 |
| 52 Week High | $17.98 | $8.27 |
Technical Indicators
Market Signals| Indicator | CYRX | PGEN |
|---|---|---|
| Relative Strength Index (RSI) | 60.29 | 62.94 |
| Support Level | $14.55 | $6.57 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.56 | 0.39 |
| MACD | 0.08 | 0.02 |
| Stochastic Oscillator | 76.11 | 75.72 |
Price Performance
Historical ComparisonAbout CYRX CryoPort Inc.
CryoPort Inc is a provider of integrated, temperature-controlled supply chain solutions for the life sciences industry, with a focus on supporting the cell and gene therapy market. The company provides services such as temperature-controlled logistics, biostorage, bioservices, cryopreservation solutions, and cryogenic systems manufacturing. It operates through two reportable segments: Life Sciences Services and Life Sciences Products. It generates the majority of its revenue from the Life Sciences Services segment.
About PGEN Precigen Inc.
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.